Cool. Let us know when you roll out the vaccine insurance plan - as it's currently impossible to get from the actual vaccine manufacturers. We'll take the 20+-year offering.
But where are the rulings? Do you have $20 million to make your case b/c we're talking about longer time frames and you have to connect a myriad of dots and pharmaceutical companies have all the money in the world? They also have the CDC-NIH-WHO in cooperation who sustain their business model.
Even trace amounts of something as seemingly benign as Carrageenan has been shown to induce Crohns and Colitis in the susceptible. If it was considered that level of safe, there's no need to hide {indemnity}, fast-track, or enter EUA status.
Vaccine providers are not even disclosing all of its contents.
Have you even glanced at the PFIZER Vaccine Doc?
https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf
This could end up being a resounding success - and I pray it is. But to make blanket statements like that is completely irresponsible - especially given the fact that you've stated you're in the industry.
You don't know. They don't know.
Everyone has to make that decision on their own, based on their set of circumstances. Health is our most precious asset by a longshot.
"You hold your life in your hands, don’t entrust it to anyone else, least of all to your chosen leaders."
— Listen, Little Man! by Wilhelm Reich
------------------------------------------
Small excerpt from PFIZER Vax Doc:
8.3.5.3. Occupational Exposure
“An occupational exposure occurs when a person receives unplanned
direct contact with a vaccine test subject, which may or may not lead to
the occurrence of an adverse event. These people may include health care
providers, family members, and other people who are around the trial
participant.
When such exposures happen, the investigator must report them to Pfizer
saftey within 24 hours of becoming aware of when they happened,
regardless of whether or not there is an associated secondary adverse
event. This must be reported using the vaccine secondary adverse event
report form. SINCE THE INFORMATION DOES NOT PERTAIN TO A PARTICIPANT
INVOLVED IN THE STUDY, THE INFORMATION WILL BE KEPT SEPARATE FROM THE
STUDY.”
TO CLARIFY: Vaccine study participants become super spreaders of
something, they don’t say what it is, but it triggers secondary
adverse events in people that never had the vax, when they are exposed
to people who did have the vax.
The investigator must report EDP to Pfizer Safety within 24 hours of the
investigator’s awareness, irrespective of whether an SAE has occurred.
The initial information submitted should include the anticipated date of
delivery (see below for information related to termination of
pregnancy).
* If EDP occurs in a participant or a participant’s partner, the
investigator must report this information to Pfizer Safety on the
Vaccine SAE Report Form and an EDP Supplemental Form, regardless of
whether an SAE has occurred. Details of the pregnancy will be collected
after the start of study intervention and until 6 months after the last
dose of study intervention.
* If EDP occurs in the setting of environmental exposure, the
investigator must report information to Pfizer Safety using the Vaccine
SAE Report Form and EDP Supplemental Form. Since the exposure
information does not pertain to the participant enrolled in the study,
the information is not recorded on a CRF; however, a copy of the
completed Vaccine SAE Report Form is maintained in the investigator site
file. Follow-up is conducted to obtain general information on the
pregnancy and its outcome for all EDP reports with an unknown outcome.
The investigator will follow the pregnancy until completion (or until
pregnancy termination) and notify Pfizer Safety of the outcome as a
follow-up to the initial EDP Supplemental Form. In the case of a live
birth, the structural integrity of the neonate can be assessed at the
time of birth. In the event of a termination, the reason(s) for
termination should be specified and, if clinically possible, the
structural integrity of the terminated fetus should be assessed by gross
visual inspection (unless preprocedure test findings are conclusive for
a congenital anomaly and the findings are reported). Abnormal pregnancy
outcomes are considered SAEs. If the outcome of the pregnancy meets the
criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion,
intrauterine fetal demise, neonatal death, or congenital anomaly), the
investigator should follow the procedures for reporting SAEs. Additional
information about pregnancy outcomes that are reported to Pfizer Safety
as SAEs follows:
* Spontaneous abortion including miscarriage and missed abortion;
* Neonatal deaths that occur within 1 month of birth should be reported,
without regard to causality, as SAEs. In addition, infant deaths after 1
month should be reported as SAEs when the investigator assesses the
infant death as related or possibly related to exposure to the study
intervention. Additional information regarding the EDP may be requested
by the sponsor. Further follow-up of birth outcomes will be handled on a
case-by-case basis (eg, follow-up on preterm infants to identify
developmental delays). In the case of paternal exposure, the
investigator will provide the participant with the Pregnant Partner
Release of Information Form to deliver to his partner. The investigator
must document in the source documents that the participant was given the
Pregnant Partner Release of Information Form to provide to his partner.
8.3.5.2. Exposure During Breastfeeding An exposure during breastfeeding
occurs if:
* A female participant is found to be breastfeeding while receiving or
after discontinuing study intervention.
* A female is found to be breastfeeding while being exposed or having
been exposed to study intervention (ie, environmental exposure). An
example of environmental exposure during breastfeeding is a female
family member or healthcare provider who reports that she is
breastfeeding after having been exposed to the study intervention by
inhalation or skin contact. The investigator must report exposure during
breastfeeding to Pfizer Safety within 24 hours of the investigator’s
awareness, irrespective of whether an SAE has occurred. The information
must be reported using the Vaccine SAE Report Form. When exposure during
breastfeeding occurs in the setting of environmental exposure, the
exposure information does not pertain to the participant enrolled in the
study, so the information is not recorded on a CRF. However, a copy of
the completed Vaccine SAE Report Form is maintained in the investigator
site file. An exposure during breastfeeding report is not created when a
Pfizer drug specifically approved for use in breastfeeding women (eg,
vitamins) is administered in accord with authorized use. However, if the
infant experiences an SAE associated with such a drug, the SAE is
reported together with the exposure during breastfeeding.
Here’s the clear part of this, that everyone can understand:
8.3.5.3. Occupational Exposure An occupational exposure occurs when a
person receives unplanned direct contact with the study intervention,
which may or may not lead to the occurrence of an AE. Such persons may
include healthcare providers, family members, and other roles that are
involved in the trial participant’s care. The investigator must report
occupational exposure to Pfizer Safety within 24 hours of the
investigator’s awareness, regardless of whether there is an associated
SAE. The information must be reported using the Vaccine SAE Report Form.
Since the information does not pertain to a participant enrolled in the
study, the information is not recorded on a CRF; however, a copy of the
completed Vaccine SAE Report Form is maintained in the investigator site
file.
